Results 101 to 110 of about 2,997 (148)

Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three-period, cross-over, placebo- and positive-controlled study

, 2013
Objective Glycopyrronium (NVA237), a once-daily long-acting muscarinic antagonist, has recently been approved for the treatment of patients with chronic obstructive pulmonary disease (COPD).
Uziel-Fusi, Susan, Drollmann, Anton Franz, Hara, Hisanori, Sechaud, Romain, winkle, peter   +4 more
core  

Glycopyrronium Bromide versus Droperidol for Prophylaxis of Postoperative Nausea and Vomiting in Hysteroscopic Day Surgery: A Randomized, Double-Blind, Non-Inferiority Trial. [PDF]

Drug Des Devel Ther
Wang X, Sun N, Xiao M, Chen Z, Yang X, Ren H, Ji F, Xiao H.   +7 more
europepmc   +1 more source

Glycopyrronium Bromide versus Droperidol for Prophylaxis of Postoperative Nausea and Vomiting in Hysteroscopic Day Surgery: A Randomized, Double-Blind, Non-Inferiority Trial

Drug Design, Development and Therapy
Xiaoqian Wang,1 Nenghong Sun,1 Ming Xiao,2 Ziyuan Chen,1 Xiaodan Yang,1 Haijuan Ren,1 Fanceng Ji,1,* Hongyi Xiao1,*1Department of Anesthesiology, Weifang People’s Hospital, Weifang, 261041, People’s Republic of China; 2Department of Pain,
Wang X, Sun N, Xiao M, Chen Z, Yang X, Ren H, Ji F, Xiao H   +7 more
doaj  

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Response to Letter]. [PDF]

Int J Chron Obstruct Pulmon Dis
Cherian M, Suissa S.
europepmc   +1 more source

Safety analysis of long-acting dual bronchodilator after market approval: a real-world study from FDA Adverse Event Reporting System (FAERS) database. [PDF]

J Thorac Dis
Gao S, Zhuang W, Song Q, Yan D, Chen L, Lai Z, Cheng Y, Yang X, Hu S.   +8 more
europepmc   +1 more source

The precision bronchodilator therapy in airflow limitation with asthma defining reversibility: An appraisal through pharmaco-responsiveness-based real-world observation. [PDF]

Lung India
Bhattacharyya P, Sen S, Ghosh S, Kar A.
europepmc   +1 more source

Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy. [PDF]

ERJ Open Res
Canonica GW, Singh D, Papi A, Brusselle G, Piraino A, Franzini L, Vele A, Hernandez G, Skloot G, Virchow JC.   +9 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Letter]. [PDF]

Int J Chron Obstruct Pulmon Dis
Wedzicha JA, Kiran A.
europepmc   +1 more source

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study. [PDF]

Int J Chron Obstruct Pulmon Dis
Cherian M, Dell'Aniello S, Suissa S.
europepmc   +1 more source

Verification of Budesonide/Glycopyrronium/Formoterol (BGF) Triple Therapy in the Department of Cardiology: A Pilot Study. [PDF]

Cureus
Kamihara T, Kaneko S, Omura T, Murohara T, Shimizu A.   +4 more
europepmc   +1 more source